Vinflunine
As of the edition of 20 October 2026, Vinflunine is a small molecule: marketed, first approved in 2009 (EU).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Javlor
- First approved
- 21 September 2009 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Pierre Fabre
- Registered trials
- 25, 6 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Lungs and airways; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 12 | 9 | 0 | 3 |
| Phase 3 | 9 | 6 | 1 | 2 |
| All trials | 25 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pierre Fabre | Applicant and Lead sponsor of trials | 2005 to now |